Medios AG Announces Strong Performance in 2023 and Promising Outlook for 2024 and 2025

Medios AG, a leading specialty pharma solutions provider in Germany, reported a notable increase in its financial performance for the year 2023. The company's consolidated revenue saw a 10.8% jump to approximately €1.8 billion, aligning with its latest forecast. Additionally, its EBITDA pre1 experienced a 10.3% rise to about €60.5 million, surpassing the most recent prediction of around €60 million. The EBITDA pre1 margin remained steady at 3.4%.

In 2023, Medios AG's Pharmaceutical Supply segment recorded a revenue of €1,558 million, marking a 12.1% increase from the previous year. Meanwhile, the EBITDA pre1 in this segment surged by 22.8% to €46.7 million. The Patient-Specific Therapies segment also saw growth, with revenue reaching €226.0 million, a 2.7% rise, though its EBITDA pre1 witnessed an approximately 8.0% decrease mainly due to regulatory price reductions since September 2022.

Looking ahead, Medios AG has set ambitious goals for 2024 and 2025, forecasting significant revenue and EBITDA pre1 increases. For 2024, the company anticipates revenue between €1.9 billion and €2.1 billion, with EBITDA pre1 expected to be between €82 million and €91 million. By 2025, Medios aims for revenue of around €2.15 billion and EBITDA pre1 of approximately €110 million, projecting a margin boost to 5.1%. These projections are partly based on the anticipated full consolidation of Ceban, a Dutch market leader in pharmaceutical compounding services, from May 1, 2024.